Kiran Bhavaraju-Sanka, MD, and Beth Stein, MD, focus on the best and most effective methods of engaging patients who have ...

Telitacicept met primary and all secondary endpoints, demonstrating clinically meaningful improvements in disease activity versus placebo~71.8% ...

DexCom › One way to earn above-average market returns -- which isn't always easy -- is to invest in companies that have lagged the market but are likely to recover over the long run. As the basic ...

Myasthenia gravis is a rare disease where the immune system attacks the communication between nerves and muscles, causing weakness. It often affects the muscles used for eye movement, facial ...

Dianthus Therapeutics is offering Nanjing Leads Biolabs up to $1 billion biobucks for licensing rights to a bispecific antibody designed to treat certain autoimmune disorders. | Dianthus Therapeutics ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that it will present more than 30 ...

Amidst the market environment, the portfolio outperformed the Russell Midcap Growth Index in the third quarter. Read more ...

Bristol Myers Squibb to Present Data at ESMO® 2025 Showcasing Progress of Oncology Portfolio Across Diverse Tumor Types ...

Detailed price information for Dianthus Therapeutics Inc (DNTH-Q) from The Globe and Mail including charting and trades.

Detailed price information for Bayer Aktienges ADR (BAYRY) from The Globe and Mail including charting and trades.

Lara Vukelich is a freelance writer in San Diego, California. She writes creative content and SEO-driven copy that can be found everywhere from Huffington Post and Quiet Revolution to Expedia, ...